Generic Products (December 2019)

Marketed by: ANI Pharmaceuticals

Compare To: Aggrenox

Indicated to reduce the risk of stroke in patients with transient ischemia of the brain or completed ischemic stroke due to thrombosis, the capsules are available in a strength of aspirin 25 mg and dipyridamole 200 mg. According to the National Center for Biotechnical Information, 8 of 10 strokes are the result of cerebral ischemia. ANI Pharmaceuticals acquired the rights to launch the drug in 2018 and is now one of 6 suppliers of this drug in the US market.

Dosage Form: Capsules

For more information: anipharmaceuticals.com

Paliperidone Extended-Release Tablets

Marketed by: Amneal Pharmaceuticals

Compared to: Invega

Available in strengths of 1.5, 3.0, 6.0, and 9.0 mg, paliperidone extended-release tablets are used to treat schizoaffective disorder and schizophrenia in adults and adolescents between 12 and 17 years. Commonly reported adverse effects include akathisia, drowsiness, and tachycardia. Like that of other atypical antipsychotic medications, the drug’s therapeutic efficacy is thought to result from mixed central serotonergic and dopaminergic antagonism.

Dosage Form: Tablets

For more information: amneal.com

Bimatoprost Ophthalmic Solution 0.03%

Marketed by: Alembic Pharmaceuticals

Compared to: Lumigan

The first ophthalmic glaucoma treatment released by Alembic, the bimatoprost ophthalmic solution 0.03% is indicated for the reduction of elevated intraocular pressure associated with ocular hypertension or open-angle glaucoma. The eye drops work by increasing the amount of fluid draining from the eye. The most common adverse effects include hypertrichosis of the eyelid, although body aches, cough, and ear congestion have also been noted.

Dosage Form: Eye drops

For more information: alembicpharmaceuticals.com

Dicylomine Hydrochloride Injectable

Marketed by: Camber Pharmaceuticals

Compared to: Bentyl

The dicyclomine hydrochloride injectable is available in 20mg/2 mL -5x2mL single dose vials for the treatment of functional bowel or irritable bowel syndrome. While the dosage should be adjusted based on individual patient needs, the started dose recommendation for intramuscular administration is 10 mg to 20 mg 4 times a day, for no more than 1 or 2 days when patients cannot take oral administration. The most common adverse reactions include dry mouth, dizziness, blurry vision, nausea, somnolence, asthenia, and nervousness.

Dosage Form: Intramuscular injection

For more information: camberpharma.com